Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
← catalyst calendarNCT01526681 · readout ≤ 834 d
Sponsored by Axogen Corporation (industry) · AXGN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
3,126actual
Sites
49
Countries
Austria, Canada, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Nov 2008 | not stated | When the study began enrolling |
| Primary completion | Nov 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2012-02-06 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Peripheral Nerve Injuries
Interventions
- Other: Processed Human Nerve Graft
- Other: Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.
- Other: Autogenous Nerve Graft
- Device: Nerve Tube Conduit
- Procedure: Autologous Breast Reconstruction with Neurotization
- Procedure: Autologous Breast Reconstruction without Neurotization
Primary outcomes
what the primary-completion date above is the date OFAvance Nerve Graft: Incidence of Avance Nerve Graft Related Adverse Events
measured Through study completion or until lost to follow-up, approximately 3 years
RANGER and MATCH: Sensory Function as measured by Medical Research Council Classification (MRCC) for sensory recovery
measured Through study completion or until lost to follow-up, approximately 3 years
RANGER and MATCH: Motor Function as measured by Medical Research Council Classification (MRCC) for motor recovery
measured Through study completion or until lost to follow-up, approximately 3 years
Sensation-NOW- Breast Neurotization: Sensory Function Post Autologous Breast Reconstruction
measured Through study completion or until lost to follow-up, approximately 3 years
Sensation-NOW- Breast Neurotization: Quality of Life Measurement Post Autologous Breast Reconstruction
measured Through study completion or until lost to follow-up, approximately 3 years
Incidence of conduit, autograft, or procedure related adverse events
measured Through study completion or until lost to follow-up, approximately 3 years
Permalink · AXGN's whole pipeline · Catalyst calendar · Every registered study · What changed